drugset / Trial / NCT07034183
A First-in-Human Study of PRD001
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of PRD001 in healthy participants and to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of PRD001 in participants with borderline/mild hyper-LDL-cholesterolemia and mild fatty liver.
Timeline
- Start
- 2025-06-19
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRD001 | Unknown | — | Oral |
Indications
No indication recorded.